Inflammation and Platelet Activation After COVID-19 Vaccines – Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and ThrombosisCOVID-19 백신 후 염증 및 혈소판 활성화 - 백신 유도 면역 혈소판 감소증 및 혈전증 뒤에 가능한 메커니즘Controlled Clinical Trial Published on 2021-11-232022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, [키워드] Activation Adenovirus age aggregation antibodies antibody antibody production cascade Coagulation complex Complication component COVID-19 COVID-19 pandemic COVID-19 vaccine CRP E-selectin endothelial Epidemiological study event excessive inflammation Gender groups Head-to-head comparison healthy controls ICAM-1 IL-10 IL-1β IL-6 IL-8 increase in individual Inflammation Inflammatory initial Johnson & Johnson marker mRNA mRNA vaccination mRNA vaccine P-selectin pathogenesis of COVID-19 PF4 Platelet platelet activation platelet factor 4 positive promote proportion Prospective Study provided TGF-β the vaccine threshold thrombin thrombocytopenia Thromboembolic event thrombosis TNF-α TTS vaccinated individual vaccination Vaccine Vaccines Vascular VCAM-1 VITT Whole blood [DOI] 10.3389/fimmu.2021.779453 PMC 바로가기 [Article Type] Controlled Clinical Trial
Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin StudyConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 바이오마커, [키워드] Activation active cancer administration Against antibody assessment Biomarker Blood blood sample BNT162b2 BNT162b2 vaccine calculated centrifugation collected conducted Control control group controls COVID-19 COVID-19 vaccine E-selectin Effect endothelial Endothelial cell Endothelium Evidence expected Factor first dose France funding FVIII groups Health Health care worker Hospital admission Host hypercoagulability immune response individual inflammatory reaction inhibitor Injury less limit Mild MRI mRNA mRNA vaccines no difference not significantly different of BNT162b2 pathway Patient Patients with cancer peak PF4 Pfizer/BioNTech plasma Platelet platelet activation Prevent Probably procoagulant Prospective prospective observational study provoke raised reported resulting risk Sample severe disease shown significantly higher significantly increased stratified subject Support symptomatic infection temperature TFPI the spike protein thrombin thrombosis thrombotic complication thrombotic event tissue triggered UNL vaccinated individual vaccinated individuals vaccination Vaccine Vaccines Venous thrombosis virus von Willebrand factor were assessed worker [DOI] 10.1182/blood-2021-146803 [Article Type] Conference abstract
TEG ® , Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 CoagulopathyReview Published on 2021-11-182022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Activation addition Anticoagulant approach blood clotting caused circulating circulation clinical trials Coagulopathy consumptive coagulopathy COVID-19 COVID-19 patient disease severity dysfunction Efficacy endothelial function Endothelium Factor fibrinolysis Guiding highlight Immune cell Inflammatory Interaction intrinsic low molecular weight maintain management mapping outcome pathway physiological state Platelet platelet activation Platelets Prophylactic receptor reduced required severe COVID-19 severe COVID-19 disease therapeutic Trial von Willebrand factor vWF [DOI] 10.3390/jcm10225381 PMC 바로가기 [Article Type] Review
Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic ImplicationsCOVID-19에서 혈소판 염증 및 내피 손상의 병원성 근거: 현재 연구 결과 및 치료적 시사점Review Published on 2021-11-082022-09-10 Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 유전자 메커니즘, 치료제, [키워드] activities acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Atypical B cell responses Basis cardiovascular risk factors cause caused coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 current dry cough dysregulated dysregulated immune responses Endothelial dysfunction endothelial injury exacerbated Fever finding global pandemic high mortality highlight immune evasion immune responses Inflammation interferon interferon signaling interstitial pneumonia knowledge leads mechanisms morbidity Most patients multiple organ failure Organ failure Pathogenesis pathogenesis of COVID-19 pathogenic patients platelet activation platelet hyperactivation public health respiratory respiratory distress resulting SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe cases suppression symptoms of COVID-19 syndrome T cell therapeutic strategy Therapeutics Thromboembolism Thromboinflammation thrombosis [DOI] 10.3390/ijms222112081 PMC 바로가기 [Article Type] Review
To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia응고하거나 응고하지 않습니까? 광고는 질문입니다-백신 유발 혈전성 혈소판 감소증과 관련된 메커니즘에 대한 통찰력Article Published on 2021-11-012022-09-11 Journal: Journal of thrombosis and haemostasis : JTH [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] Ad26.COV2.S Adenovirus Administered antibodies AstraZeneca Canada caused ChAdOx1 ChAdOx1 nCoV-19 characterized COVID-19 COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine D-dimer Diagnosis dose elevated Europe first dose help highlighting immune janssen management mechanism pathogenic PF4 Platelet platelet activation potential mechanism potential mechanisms reported required Research thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenia Vaccine Vaccines [DOI] 10.1111/jth.15485 PMC 바로가기 [Article Type] Article
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets항-SARS-CoV-2 스파이크 IgG의 비정상적인 글리코실화는 혈소판에 대한 전혈전성 자극입니다Article Published on 2021-10-212022-09-12 Journal: Blood [Category] MERS, SARS, 진단, [키워드] Activation acute respiratory syndrome adaptive anti-SARS-CoV-2 Anti-spike antibody cause contribute coronavirus coronavirus disease COVID-19 Critical Critically ill dependent on domain Evidence excessive immune response glycosylation immune complex Immunity Immunoglobulin in vitro inhibit kinase P2Y12 pathogenic Patient Platelet platelet activation prothrombotic respiratory problem SARS-CoV-2 spike protein severe COVID-19 severely ill patient small molecule spike IgG subset susceptible the timing therapeutic thrombosis tyrosine von Willebrand factor with COVID-19 [DOI] 10.1182/blood.2021011871 PMC 바로가기 [Article Type] Article
Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19Review Published on 2021-10-162022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS, [키워드] accumulating aggregation alteration Anti-inflammatory therapy Atherosclerosis Bioavailability Bone marrow cardiovascular disease changes characterized Complication Coronavirus disease-19 COVID-19 Critical Cytokines dysregulated endothelial Endothelium Evidence focus functional implicated induce Inflammation Inflammatory Interaction mediator Modification morbidity and mortality myeloperoxidase Neutrophil extracellular trap pandemic Platelet platelet activation pro-inflammatory cytokine receptor receptors thrombotic Thrombotic complications TNF-α Vascular endothelium von Willebrand factor [DOI] 10.3390/ijms222011170 PMC 바로가기 [Article Type] Review
Therapeutic Potential of Annexins in Sepsis and COVID-19Pharmacology Published on 2021-09-092022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] adaptive analogue animal model Annexin annexin (A1, A2 and A5) Anti-inflammatory caused Cell cell membrane clinical trial Coagulation condition COVID-19 demonstrated disease Effect Efficacy healthcare Human Immunity IMPROVE Inflammation Inflammatory inflammatory mediator inhibit investigated involved Ischemia ischemic injury mechanism modulation mortality rate MOST Myocardial infarction organ function outcome pathophysiology Patient peptide phagocytosis physiological platelet activation positive Potential potential therapies potential therapy Prevalence PROTECT Protective reduce reduce mortality reperfusion injury Research Safety SARS-COV-2 infection Sepsis severe COVID-19 patients shielding Support systemic effects therapeutic agent Treatment [DOI] 10.3389/fphar.2021.735472 PMC 바로가기 [Article Type] Pharmacology
Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic ThrombocytopeniaInfectious Disease Published on 2021-09-012022-10-31 Journal: Cureus [Category] COVID-19, [키워드] adverse effect antibody AstraZeneca AstraZeneca vaccine ChAdOx1 nCoV-19 challenge clinical clinical history coronavirus disease COVID-19 COVID-19 vaccine described Diagnosis disorder ELISA enzyme-linked immunosorbent first dose functional heparin HIPAA immune individual Intracerebral hemorrhage Oxford-AstraZeneca Patient PF4 platelet activation positive prothrombotic receiving SARS-CoV-2 tested thrombocytopenia thrombosis thrombotic Vaccines [DOI] 10.7759/cureus.17637 PMC 바로가기 [Article Type] Infectious Disease
COVID-19 Immunobiology: Lessons Learned, New Questions AriseImmunology Published on 2021-08-262022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] Activation Adaptive immune response adaptive immune system Asymptomatic autoantibody Autoimmune Autoimmunity cellular cellular senescence complement COVID-19 COVID-19 patient cytokine deregulation disease Diseases driven by endothelial Endothelitis Evidence Factor heterogeneity immune immune deregulation immunothrombosis Inflammation Inflammatory cell death Inflammatory response interferon lesson Mortality NET New offer pathophysiology phenotypic platelet activation responses SARS-CoV-2 senescence severe COVID-19 severe disease spatiotemporal subsequent the disease Treatment variety [DOI] 10.3389/fimmu.2021.719023 PMC 바로가기 [Article Type] Immunology